When a new class of cholesterol-lowering medications called PCSK9 inhibitors hit the market in 2015, they were instantly controversial because of their price. But a new study suggests payers may be going overboard in refusing to authorize prescriptions for patients who need them.
from Forbes Real Time https://www.forbes.com/sites/arleneweintraub/2017/10/30/half-of-patients-with-super-high-cholesterol-cant-get-drugs-that-could-help/
via IFTTT
No comments:
Post a Comment